You are here: Industry Insights > Fruquintinib

News List

Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation PharmaSources/Xiaoyaowan
July 06, 2020
Hutchison MediPharma’s targeted anticancer drug: fruquintinib has recently received the Fast Track designation granted by the FDA for the treatment of patients with metastatic colorectal cancer (mCRC).
Innovent and Hutchison to test sintilimab and fruquintinib combination pharmaceutical-technology
December 03, 2018
Innovent Biologics (Suzhou) has entered into a global collaboration agreement to evaluate the safety of its sintilimab in combination with Hutchison MediPharma’s fruquintinib .....
Chi-Med’s fruquintinib gets approval for colorectal cancer in China pharmaceutical-technology
September 11, 2018
Hutchison China MediTech (Chi-Med) has secured approval from the National Medical Products Administration of China (NMPA) for the use of fruquintinib capsules to treat metastatic colorectal cancer (CRC).
Finally! The 100% Chinese-produced Targeted Anti-cancer Drug Fruquintinib Developed by Hutchison MediPharma for 13 Years to be Marketed Caicai
September 07, 2018
The blockbuster targeted anti-cancer drug Fruquintinib that I’ve been following has finally achieved new significant progress recently.
Rise! Chinese-produced Drug! Fruquintinib Opens Up a New Direction for the Treatment of Advanced Colorectal Cancer Ye Fenghong
July 24, 2018
Colorectal cancer is one of the common malignancies, with morbidity and mortality gradually rising worldwide.